Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Chien

Showing results (531-540 of 550) with videos related to

Pageof 55
Sort By:
Cancer|December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemiaAlexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Leukemia Research|August 23, 2024
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysisDavid McCall, Tareq Abuasab, Juan Jose Rodriguez-Sevilla, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Hematological Oncology|August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndromeChristopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Blood|July 13, 2023
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemiaJayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus VenetoclaxAlexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
The New England Journal of Medicine|August 13, 2015
A Randomized Trial of Intrapartum Fetal ECG ST-Segment AnalysisMichael A Belfort, George R Saade, Elizabeth Thom, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With OlutasidenibKelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Journal of Hematology & Oncology|June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II studyNicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
American Journal of Hematology|April 3, 2021
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Faezeh Darbaniyan, et al.
Pageof 55

Showing results (531-540 of 550) with videos related to

Sort By:
Pageof 55
Cancer|December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemiaAlexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Leukemia Research|August 23, 2024
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysisDavid McCall, Tareq Abuasab, Juan Jose Rodriguez-Sevilla, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Hematological Oncology|August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndromeChristopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Blood|July 13, 2023
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemiaJayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus VenetoclaxAlexandre Bazinet, Sai Prasad Desikan, Ziyi Li, et al.
The New England Journal of Medicine|August 13, 2015
A Randomized Trial of Intrapartum Fetal ECG ST-Segment AnalysisMichael A Belfort, George R Saade, Elizabeth Thom, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With OlutasidenibKelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Journal of Hematology & Oncology|June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II studyNicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
American Journal of Hematology|April 3, 2021
Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Faezeh Darbaniyan, et al.
Pageof 55